Kornimate/medical-research-clean huggingface dataset:
effectiveness of a web-based intervention for guardians of children whose one parent has murdered the other

Conditions: Post-Traumatic Stress Disorder

Summary: this study will determine whether a specialized web site geared for the guardians of children whose one parent has murdered the other can increase guardian capabilities, reduce guardian stress, and improve child behavior and mental health.

intraparental homicide (iph), when one parent kills the other, leaves approximately 4,000 children bereaved each year, adding to a total of 70,000 currently in the united states. although few studies have focused on this phenomenon, available data indicate children of iph suffer short- and long-term mental health consequences, including post-traumatic stress disorder (ptsd). prior research also indicates that guardians, often family members under stress themselves, do not know how to help the children. no interventions directed at guardians of child survivors of iph are found in scientific and clinical literature. use of a specialized web site called an interactive healthcare communication application (ihca) has been found effective in treating multiple health conditions, including breast cancer in women and asthma in children. this study aims to refine an ihca web site for use by guardians of child survivors of iph, to determine the safety and effectiveness of this web site, and to determine how it is used by targeted guardians. in the first phase of this study researchers will develop the ihca based on feedback from a small focus group of guardians of child survivors of iph. then guardians of survivors of iph up to 16 years old will be randomly assigned either to receive access to the ihca created for them or to have access only to generally available internet information. the ihca will have six components: (1) an instant library of articles on topics of interest; (2) a resource directory of both national and local support and service organizations; (3) access to a peer communication system; (4) a frequently asked questions section, updated with responses to user generated questions; (5) an "ask an expert" system staffed by researchers; and (6) personal stories of others dealing with iph. participants with access to the ihca will receive print and phone instructions explaining the web site and have their usage monitored by tracking software. those in the control group will be directed to a web site linking to publically available, pre-existing support web sites. after 16 weeks of unlimited access to the ihca or control group web sites from their home computers, all participants will complete four evaluation reviews: the family crisis oriented personal evaluation scales, the parenting stress index, the child behavior checklist, and the child ptsd inventory - parent.

Eligibility criteria:
inclusion criteria: * able to speak and read english at a 7th grade level * guardian of a child survivor of parental homicide aged 0 to 16 years exclusion criteria: * none

Keywords: intimate partner homicide parental homicide guardians of child survivors of parental homicide post-traumatic stress disorder uxoricide project
follicular fluid raman shifts and ivf outcomes

Conditions: Polycystic Ovary Syndrome; IVF

Summary: this study intends to collect about 150 cases of follicular fluid samples from pcos and non-pcos infertility patients undergoing in vitro fertilization (ivf) or intracytoplasmic sperm injection (icsi) cycles (in clinical routines).we tend to detect raman metabolic profile of the follicular fluid of the pcos and non-pcos groups, and find the correlation between the metabolic profile of the follicular fluid of pcos patients and the oocyte quality, ivf outcome and subsequent embryo development are also under investigation. metabolomics analysis was applied to look for markers of follicular fluid in pcos patients, and further exploring data and strategies to improve the embryonic development potential and ivf outcome of pcos patients.


Eligibility criteria:
inclusion criteria: * patients fit the rotterdam criteria for pcos * patients under ivf cycles exclusion criteria: * patients with male factors infertility * patients with fallopian tube factors infertility
chemotherapy with anlotinib in advanced cervical cancer

Conditions: Uterine Cervical Neoplasms

Summary: study hypothesis: the primary hypothesis is whether chemotherapy with anlotinib improves overall survival in advanced cervical cancer. trial design: the study is a prospective, single-arm, observational clinical study. the study will be performed on an intent-to-treat population. all the enrolled patients received chemotherapy with anlotinib. primary endpoint: overall survival, defined as the observed length of life from entry into the study to death from any cause or the date of last contact.

patients with advanced (metastatic, persistent, and recurrent) cervical cancer will be recruited from zhongda hospital. only patients who treated with paclitaxel plus nedaplatin will be included in the analysis. all patients receive paclitaxel (135-175mg /m\^2) and nedaplatin (100 mg/m\^2) infusion on day 1, and then take anlotinib 12mg/d orally on day 7-21, every 3 weeks. once patients reached cr or pr, anlotinib was continued on 12mg/d maintenance therapy until disease progression or unacceptable toxicity was noted.

Eligibility criteria:
inclusion criteria: * patients with advanced (metastatic, persistent, and recurrent) cervical cancer confirmed by imaging and unsuitable for surgery and radiotherapy . * eastern cooperative oncology group (ecog) performance score(ps) 0-1 * estimated life expectancy \> 3 months * adequate bone marrow function: hemoglobin \> 90 g/l, absolute neutrophil count(anc) \> 1.5 × 10\^9/l, platelet \> 80 × 10\^9/l); * adequate hepatic function: total bilirubin \< 1.5 times the upper limit of normal (uln), alanine aminotransferase (alt) and aspartate aminotransferase (ast)\<2.5×uln or \<5×uln for patients with liver metastases; * adequate renal function: serum creatinine \ 60 ml/min; * adequate cardiac function: left ventricular ejection fraction (lvef) \> 50%. exclusion criteria: * preexisting thyroid disease, thyroid function cannot be maintained in the normal range after treatment; * have used other anti-vegf or vegfr-targeted drugs or received immunotherapy; * a history of major surgical treatment within 4 weeks, radiotherapy within 3 weeks, and concurrent chemoradiotherapy within 6 weeks; * receiving hormone or immunosuppressive therapy for various reasons; * inability to swallow oral medication; * any malabsorption; * diseases diagnosed as severe or uncontrollable within 6 months prior to the first day of treatment. * participate in clinical trials of other antitumor drugs within 28 days prior to the start of study treatment; * the patient has comorbidities that may endanger the patient's safety or affect the patient's ability to complete the study. * according to the researcher's judgment, the patient has an accompanying disease that may jeopardize the patient's safety or affect the patient's ability to complete the study in the investigator's judgment.

Keywords: anlotinib chemotherapy advanced cervical cancer
device to assist with abdominal access during laparoscopic surgery

Conditions: Laparoscopic Surgery

Summary: the purpose of this study is to assess the safety and ease of use of a tautona pneumoperitoneum assist device (tpad) to assist with obtaining peritoneal access with a veress needle, and for placing a primary trocar, during laparoscopic surgery.


Eligibility criteria:
inclusion criteria: * age \>/= 18 * scheduled for laparoscopic surgery * able to understand and willing to sign a written informed consent form exclusion criteria: * age \< 18 * any situation where blind, peri-umbilical passage of a veress needle is contraindicated. * any situation where patients have suspected or confirmed intra-abdominal adhesions involving the peri-umbilical abdominal wall. * any situation where patients have a suspected or confirmed umbilical hernia or peri-umbilical ventral hernia. * any situation where there is not intact, uncompromised skin of the peri-umbilical region where the device is to be placed.
an email intervention to prevent iatrogenic malnutrition in the icu

Conditions: Malnutrition

Summary: this is a quality improvement research project evaluating if a targeted feedback email to clinicians impacts their nutrition delivery in the icu.

this prospective study looks to determine if a targeted email to clinicians taking care of critically ill patients will allow reduce malnutrition in the intensive care units (icu). four icus will be included: medical icu (micu), coronary care unit (ccu) and two surgical icus. the investigators will rotate a 2 month period intervention amongst the aforementioned participating icus and follow simultaneous cohorts to evaluate the effect of our intervention (email feedback to treating clinicians) on nutrition delivery in the icu. after the completion of the intervention, there will be a six-month follow-up of nutritional adequacy to assess the durability of changes in behavior.

Eligibility criteria:
inclusion criteria: * clinicians taking care of patients admitted to the icu within the past 48hrs * clinicians taking care of patients in whom enteral nutrition is prescribed exclusion criteria: * clinicians taking care of patients in whom enteral nutrition is not prescribed.

Keywords: malnutrition in the icu (caloric deficit >4000 kcal or 150 g protein deficit) or >48hrs of admission without receiving nutrition
accurate display of postpartum hemorrhage using triton (adopt)

Conditions: Post-partum Hemorrhage (PPH)

Summary: a comparison of reported estimated blood loss with quantified blood loss in all patients whose medical records indicate triton was used during their vaginal delivery.

this study is a retrospective blinded cohort trial comprised of two data collection phases. in the first phase data will be collected on all women who had vaginal deliveries between 2010 and 2015 who had a procedure code indicative of transfusion (99.0x) or received a diagnosis suggestive of peripartum hemorrhage (e.g. diagnosis x code 666.xx, 641.x, 645.x, 646.x 674.x). phase 2 will consist of all women who delivered (vaginally) at hackensackumc who had blood loss and measured quantitatively by triton and qualitatively (i.e., ebl) by obstetrician. this will be accomplished by reviewing the records of women who delivered and were discharged within the data collection period.

Eligibility criteria:
inclusion criteria: * all women who delivered (vaginally) at hackensackumc who had blood loss and measured quantitatively by triton and qualitatively (i.e., ebl) by obstetrician. * all women who had vaginal deliveries between 2010 and 2015 at hackensackumc who had a procedure code indicative of transfusion (99.0x) or received a diagnosis suggestive of peripartum hemorrhage (e.g. diagnosis x code 666.xx, 641.x, 645.x, 646.x 674.x). exclusion criteria: * women who received transfusions unrelated directly to pregnancy (e.g. renal disease, anemia of pregnancy, genetic or viral conditions causing anemia).
radical versus conservative surgical treatment of liver hydatid cysts

Conditions: Hydatid Cyst

Summary: the management of liver hydatid cysts (lhc) is controversial. surgery remains the basic treatment, and can be divided into radical and conservative approaches. the purpose of this study was to compare the outcome of radical and conservative surgery (cs) in the treatment of lhc and to evaluate the efficiency and safety of radical surgery (rs).

the management of liver hydatid cysts (lhc) is controversial. surgery remains the basic treatment, and can be divided into radical and conservative approaches. the purpose of this study was to compare the outcome of radical and conservative surgery (cs) in the treatment of lhc and to evaluate the efficiency and safety of radical surgery (rs). data from all patients with lhc treated in sahloul hospital, between january 2000 and december 2019, were retrieved from a retrospective database. to minimize selection bias, propensity score matching (psm) was performed, based on variables representing patient characteristics and operative risk factors. rs especially total pericystectomy had fewer postoperative complications and lower recurrence rate compared to cs. rs may be the preferred procedure for lhc if the expertise is available.

Eligibility criteria:
inclusion criteria: * age over 14 years old. * patients presenting liver hydatid cyst . exclusion criteria: * age less than 14 years old. * patients presenting other localization of hydtic cyst , than the liver. * calcified cysts. * patients with incomplete medical records. * patients who were lost to follow up.
optimizing the delineation of the tumour bed in breast irradiation

Conditions: Breast Cancer

Summary: the aim of the present study is: 1. to verify whether the delineation of the tumour bed, based on the combination of the visible postoperative changes and the position of the surgical clips on a ct scan in treatment position acquired 1 week before the start of the radiotherapy (rt), provides an accurate localisation of the boost volume compared to the localisation of the tumour on a pre-operative ct-scan. 2. to document the changes that occur in the tumour bed as seen on a ct scan as a function of the delay between surgery and radiotherapy. 3. to determine the ideal number and the positioning of the clips needed to reproduce the best treatment volume for the boost. 4. to propose new guidelines for tumour bed definition and delineation based on the study findings.

start of the study: february 2012

Eligibility criteria:
inclusion criteria: * breast cancer patients, without metastases, who will undergo breast conserving surgery and probably will receive adjuvant chemotherapy and thereafter radiotherapy. exclusion criteria: * metastases at time of diagnosis
the effect of omt on patients with copd: correlating pulmonary function tests with biochemical alterations

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this project proposes to test the hypothesis that osteopathic manipulative treatment (omt) given to patients with moderate to severe chronic obstructive pulmonary disease (copd) enrolled in a 12-week pulmonary rehabilitation program (prp) will result in improved respiratory pump function over and above that seen in sham and control groups. specifically, we will study the effects of three omt techniques: (a) thoracic inlet indirect myofascial release; (b) rib raising with continued stretch of the paraspinal muscle to the l2 level; and (c) cervical paraspinal muscle stretch with suboccipital muscle release. the key clinical readouts will include: spirometry, p100 (and index of diaphragm and inspiratory muscle efficiency), maximum inspiratory pressure (mip) and maximum expiratory pressure (mep), as well as laser evaluation of chest wall excursion. supplementing these objective parameters will be several more subjective clinical outcome measures: exercise tolerance (6-minute walk test), dyspnea (shortness of breath questionnaire), and quality of life questionnaire. finally, an attempt will be made to correlate biochemical alterations that may shed light on the biological mechanism underlying the omt procedures.

according to the above directions (provide a more extensice description, if desired), i am choosing to just submit the brief summary. thank you, sherman gorbis, do

Eligibility criteria:
inclusion criteria: * postbronchodilator fev1/fvc \<0.7 and fev1 \<80% predicted \[fev1 =volume that has been exhaled at the end of the first second of forced expiration\] and fvc volume of air that can be forcibly blown out after full inspiration\] * history of smoking \>20 pack-years * stable condition at inclusion with no infection or exacerbation for at least two months * optimal medical therapy for at least eight weeks with no change exclusion criteria: * history of active pulmonary disease such as asthma * positive bronchodilator test * treatment with n-acetylcysteine * previous diagnosis of hypertension or current anti-hypertensive treatment * known unstable or moderate to severe heart disease (arrhythmia, ischemic heart disease, or cardiomyopathy) * previous diagnosis of chronic illness such as diabetes, renal failure, hypercholesterolemia, hepatic cirrhosis, cancer, rheumatoid arthritis or any other systemic inflammatory disease * neuromuscular or disabling cognitive problems * engagement in any exercise-training program during the past three months * substance abuse in the preceding six months

Keywords: osteopathic manipulative treatment pulmonary function tests biochemical alterations
effects of cognitive correction and stimulus control in chronic insomnia patients

Conditions: Chronic Insomnia

Summary: this study aims to validate the effect of cognitive correction and stimulus control on correcting sleep cognitive distortions and improving maladaptive sleep behaviors.

cognitive correction aims to identify and change patients' erroneous beliefs and attitudes about sleep, which may include exaggerated sleep needs, excessive worry about the consequences of insomnia, and unrealistic expectations about bedtime. stimulus control, on the other hand, focuses on modifying patients' behaviors in bed, linking the bed with a rapid onset of sleep, and reducing the negative association between the bed and insomnia.

Eligibility criteria:
inclusion criteria: 1. meets the diagnostic criteria for insomnia disorder according to dsm-5; 2. psqi total score \> 5; 3. age ≥ 18 years, with at least a junior high school education; 4. sleep cognitive distortions assessed using the dbas-16; 5. "maladaptive sleep behavior questionnaire - 8 items" used to assess "maladaptive sleep behaviors"; 6. willing to participate in the study and sign an informed consent form. exclusion criteria: 1. presence of severe physical illness or serious mental disorders, or at risk for suicide; 2. clinically diagnosed or suspected sleep-related breathing disorders, restless legs syndrome, and circadian rhythm sleep-wake disorders; shift workers; 3. pregnant or lactating women; 4. currently undergoing any form of psychological therapy.

Keywords: chronic insomnia cognitive correction stimulus control sleep hygiene education
phase i and pharmacokinetic study of biweekly pep02 in mcrc refractory to 1st-line oxaliplatin base therapy

Conditions: Metastatic Colorectal Cancer

Summary: the purpose of this study is to evaluate the dose-limiting toxicity (dlt), toxicity profile, maximum tolerated dose (mtd) and characterize the pharmacokinetics of biweekly pep02 treatment.


Eligibility criteria:
inclusion criteria: * histopathologically confirmed metastatic colorectal cancer * documented disease progression after first-line chemotherapy containing oxaliplatin * both genders, age 18 years * ecog performance status 0 or 1 * adequate organ and marrow function * written informed consent to participate in the study exclusion criteria: * have received irinotecan treatment * with active cns metastases (indicated by clinical symptoms, cerebral edema, steroid requirement, or progressive growth) * with clinically significant gastrointestinal disorder (e.g. bleeding, inflammation, obstruction, including partial or complete obstruction secondary to peritoneal carcinomatosis, or diarrhea \> grade 1) * with uncontrolled intercurrent illness that could limit study compliance considered to be ineligible for the study by the investigators including, but not limited to, any of the following:ongoing or active infection requiring antibiotic treatment, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia psychiatric illness or social situation that would preclude study compliance * with other primary malignancies, except those remain disease-free for 3 or more years after curative treatment. * prior chemotherapy within 3 weeks * major surgery or radiotherapy within 4 weeks * prior participation in any investigational drug study within 3 weeks * history of allergic reaction to liposome product * pregnant or breastfeeding (a urine pregnancy test must be performed on all patients who are of childbearing potential before entering the study, and the result must be negative)
orthokeratology for high myopia (ohm) study

Conditions: Myopia; High Myopia

Summary: this project aims to investigate/examine high myopic subjects on full correction ortho-k (using topaz ortho-k lenses for high myopia) compared to subjects undergoing partial reduction ortho-k and their relationship with myopia and myopic progression.

for many years, commercially-available ortho-k lenses aim to reduce low - moderate myopia. attempts to use these lenses for reduction of high myopia have been shown to give rise to complications such as corneal staining and lens decentration. thus, practitioners may choose a more conservative way for high myopic children, that is, offering partial reduction ortho-k. partial reduction ortho-k is target for 4.00-5.00d reduction and the residual refractive errors will be corrected with single vision spectacles to allow good visual acuity in the daytime. partial reduction ortho-k has been shown to slow axial elongation in high myopic children, however, the main disadvantage is that the children have to wear spectacles in the daytime to correct residual refraction. euclid has recently designed a new lens, euclid's topaz, for high myopic children. it is currently commercially available to correct myopia for up to 10 d. however, evidence of its effectiveness for visual correction and slowing al growth is lacking. while numerous studies have shown that orthokeratology is an effective clinical treatment to slow axial eye growth in children, the exact mechanism underlying this reduction in myopia progression associated with orthokeratology remains unclear.

Eligibility criteria:
inclusion criteria: * myopia: at least 5.00d in one eye or in both eyes * astigmatism: ≤1.50d; with-the-rule astigmatism (axes 180 ± 30) ≤1.25d; astigmatism of other axes ≤0.50d in both eyes * anisometropia: not be more than 1.00d in the former and not more than 2.00d in the latter. * best-corrected monocular snellen visual acuity 6/7.5 or better exclusion criteria: * strabismus at distance or near * previous experience in contact lens wear or myopia control treatment (e.g. refractive therapy or progressive spectacles) * contraindication for contact lens wear and orthokeratology (e.g. limbus to limbus corneal cylinder and dislocated corneal apex) * previous history of ocular surgery, trauma, or chronic ocular disease * concurrent use of medications that may affect tear quality or contact lens wear * systemic or ocular conditions that may affect tear quality or contact lens wear (e.g allergy and concurrent medication) or that may affect refractive development (e.g down syndrome, ptosis) * poor compliance to tests (e.g poor fixation in noncontact tonometry or intolerance of lens wear) * not willing to comply with the allocated treatment, use and care of lenses and follow-up schedule

Keywords: myopia control orthokeratology children
natural history study of retinitis pigmentosa type 11

Conditions: Retinitis Pigmentosa 11; Retinitis Pigmentosa

Summary: observational study of patients with retinitis pigmentosa type 11

natural history study with clinical examination every 6 months.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of retinitis pigmentosa caused by a disease-causing mutation involving the prpf31 gene * or disease-causing mutation involving the prpf31 gene without the clinical diagnosis of retinitis pigmentosa exclusion criteria: * under 18 years * other types of retinitis pigmentosa

Keywords: retinitis rp prpf31